GB202306835D0 - Therapy - Google Patents
TherapyInfo
- Publication number
- GB202306835D0 GB202306835D0 GBGB2306835.6A GB202306835A GB202306835D0 GB 202306835 D0 GB202306835 D0 GB 202306835D0 GB 202306835 A GB202306835 A GB 202306835A GB 202306835 D0 GB202306835 D0 GB 202306835D0
- Authority
- GB
- United Kingdom
- Prior art keywords
- therapy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 238000002560 therapeutic procedure Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2306835.6A GB202306835D0 (en) | 2023-05-09 | 2023-05-09 | Therapy |
| PCT/EP2024/062876 WO2024231518A1 (en) | 2023-05-09 | 2024-05-09 | Combination therapy for bacterial infections comprising zinc-chelator, beta-lactam antibiotic and cyclic boronate beta-lactamase inhibitor |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2306835.6A GB202306835D0 (en) | 2023-05-09 | 2023-05-09 | Therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB202306835D0 true GB202306835D0 (en) | 2023-06-21 |
Family
ID=86763227
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GBGB2306835.6A Ceased GB202306835D0 (en) | 2023-05-09 | 2023-05-09 | Therapy |
Country Status (2)
| Country | Link |
|---|---|
| GB (1) | GB202306835D0 (en) |
| WO (1) | WO2024231518A1 (en) |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040225004A1 (en) | 2003-02-06 | 2004-11-11 | Bioresponse, Llc | Combined use of cruciferous indoles and chelators for the treatment of papillomavirus-related conditions |
| WO2006043153A2 (en) | 2004-10-20 | 2006-04-27 | Michel Xilinas | Use of zinc and copper chelators for the treatment of viral diseases |
| WO2009140215A2 (en) | 2008-05-11 | 2009-11-19 | Geraghty, Erin | Method for treating drug-resistant bacterial and other infections with clioquinol, phanquinone, and related compounds |
| US20110189260A1 (en) | 2008-05-30 | 2011-08-04 | University Of Cincinnati | Use of zinc chelators to inhibit biofilm formation |
| CA2780756A1 (en) | 2009-11-23 | 2011-05-26 | Prothera, Inc. | Compositions and methods comprising serratia peptidase for inhibition and treatment of biofilms related to certain conditions |
| BR112013003045B1 (en) | 2010-08-10 | 2021-08-31 | Rempex Pharmaceuticals, Inc. | Compound and its use, pharmaceutical composition, sterile container and method for preparing pharmaceutical composition for administration |
| KR102147420B1 (en) | 2012-12-07 | 2020-08-25 | 베나토알엑스 파마슈티컬스, 인크. | Beta-lactamase inhibitors |
| GB201317619D0 (en) | 2013-10-04 | 2013-11-20 | Uni I Oslo | Compounds |
| KR102396753B1 (en) | 2014-06-11 | 2022-05-12 | 베나토알엑스 파마슈티컬스, 인크. | Beta-lactamase inhibitors |
| US10294249B2 (en) | 2016-06-30 | 2019-05-21 | Qpex Biopharma, Inc. | Boronic acid derivatives and therapeutic uses thereof |
| GB201613946D0 (en) | 2016-08-15 | 2016-09-28 | Univ Oslo | Compounds |
-
2023
- 2023-05-09 GB GBGB2306835.6A patent/GB202306835D0/en not_active Ceased
-
2024
- 2024-05-09 WO PCT/EP2024/062876 patent/WO2024231518A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2024231518A1 (en) | 2024-11-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA221425S (en) | Therapy eye-mask | |
| GB202113079D0 (en) | New therapy | |
| GB202103164D0 (en) | Therapy | |
| GB202002639D0 (en) | Therapy | |
| IL319599A (en) | Combination therapy | |
| IL318268A (en) | Combination therapy | |
| GB202111035D0 (en) | Therapy | |
| GB202108303D0 (en) | Therapy | |
| GB202315877D0 (en) | Therapy | |
| GB202306826D0 (en) | Therapy | |
| GB202306833D0 (en) | Therapy | |
| GB202306835D0 (en) | Therapy | |
| GB202303026D0 (en) | Therapy | |
| GB202219335D0 (en) | Therapy | |
| GB202218595D0 (en) | Therapy | |
| GB202215997D0 (en) | Therapy | |
| GB202214514D0 (en) | Therapy | |
| GB202318311D0 (en) | Combination therapy | |
| GB202317996D0 (en) | Combination therapy | |
| GB202316168D0 (en) | Combination therapy | |
| GB202315149D0 (en) | Combination therapy | |
| GB202314243D0 (en) | Combination therapy | |
| GB202314157D0 (en) | Combination therapy | |
| GB202306663D0 (en) | Combination therapy | |
| GB202218974D0 (en) | Combination therapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AT | Applications terminated before publication under section 16(1) |